Last updated on February 2019

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Brief description of study

The primary purpose of this study is to assess the preventive vaccine efficacy (VE), safety and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and aluminum-phosphate adjuvanted Clade C gp 140 for the prevention of Human Immuno Virus (HIV) infection in HIV-seronegative women residing in sub-Saharan Africa from confirmed HIV-1 infections diagnosed between the Month 7 and Month 24 visits.

Clinical Study Identifier: NCT03060629

Contact Investigators or Research Sites near you

Start Over

Study Contact

Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital
Diepkloof, South Africa
  Connect »

Study Contact

Perinatal HIV Research Unit (PHRU), Kliptown
Soweto, South Africa
  Connect »

Study Contact

The Aurum Institute Rustenburg Clinical Research Site
Rustenburg, South Africa
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.